Stocklytics Platform
Asset logo for symbol BMRN
BioMarin Pharmaceutical
BMRN79
$66.39arrow_drop_down0.52%-$0.35
High Quality
Asset logo for symbol BMRN
BMRN79

$66.39

arrow_drop_down0.52%

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

BioMarin Pharmaceutical (BMRN) Stocklytics Forecast

BioMarin Pharmaceutical Inc (BMRN) is a leading biotechnology company focused on developing innovative therapies for patients with rare genetic diseases. With a strong pipeline of potential treatments and a track record of success, BioMarin is well-positioned for future growth. The company's stock price has been a topic of interest for investors and analysts, with many seeking to predict its future performance.
While it is impossible to predict exactly where BioMarin's stock price will be in the future, there are several factors that could influence its trajectory. One important factor is the company's pipeline of new therapies. BioMarin has a number of promising drugs in development, including treatments for rare diseases such as phenylketonuria and hemophilia. If these drugs are successful in clinical trials and receive regulatory approval, they could drive significant revenue growth for the company and potentially boost its stock price.
add BioMarin Pharmaceutical  to watchlist

Keep an eye on BioMarin Pharmaceutical

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is the analyst price prediction for BioMarin Pharmaceutical (BMRN) stock?

Analysts have set a target price of $111.18 for BioMarin Pharmaceutical (BMRN), based on forecasts from 22 analysts. The predicted price range extends from a high of $140 to a low of $73. This represents a potential increase of up to 110.86% and a decrease of 9.95% from the current price of $66.4. These forecasts are as of 2023 Jun 30.
help

What are the analyst ratings for BioMarin Pharmaceutical (BMRN) stock?

The analyst ratings for BioMarin Pharmaceutical (BMRN) are distributed as follows: 22 analysts recommend buying, 5 have a neutral stance, and 0 suggest selling. The prevailing sentiment among the total of 27 analysts leans towards a buy rating. These ratings indicate the general sentiment among the analysts covering BioMarin Pharmaceutical .
help

What is the AI price prediction for BioMarin Pharmaceutical (BMRN) stock?

At present, there is no AI or machine-learning-based price prediction available for BioMarin Pharmaceutical (BMRN) stock. The lack of a forecast could stem from various factors, such as inadequate data or the necessity for model recalibration.

Take Your Investments to a Whole New Level